GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Business Overview - GeneDx has been operating for 25 years, focusing on diagnosing rare diseases, particularly through whole exome and whole genome sequencing technology [1] - The company has recently intensified its commercial efforts since 2021, refining its technology over the past two decades [1] Market Position and Strategy - The core of GeneDx's business involves expert clinical geneticists in the United States, with around 2,000 professionals utilizing exome and genome sequencing as a last-resort diagnostic tool for complex cases [2] - Historically, GeneDx was not widely recognized outside of the expert genetics community, indicating a niche market focus [2]